18F-FDG imaging: Pitfalls and artifacts

Journal of Nuclear Medicine Technology

Volumn 33, Issue 3, 2005, Pages 145-155

  Abouzied, Mohei M ^a   Crawford, Elpida S ^a   Nabi, Hani Abdel ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

18F FDG imaging; Artifacts

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

BONE MARROW; DIAGNOSTIC IMAGING; GASTROINTESTINAL TRACT; HEAD AND NECK CANCER; HEART MUSCLE; MUSCLE CONTRACTION; POSITRON EMISSION TOMOGRAPHY; REVIEW; SPLEEN; THYMUS; UROGENITAL SYSTEM; ANTIBODY SPECIFICITY; ARTIFACT; CLINICAL PRACTICE; DIAGNOSTIC ERROR; HUMAN; METABOLISM; METHODOLOGY; NEOPLASM; PRACTICE GUIDELINE; SCINTISCANNING; TISSUE DISTRIBUTION;

ARTIFACTS; DIAGNOSTIC ERRORS; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASMS; ORGAN SPECIFICITY; PHYSICIAN'S PRACTICE PATTERNS; POSITRON-EMISSION TOMOGRAPHY; PRACTICE GUIDELINES; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 33644700383     PISSN: 00914916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Gambhir SS, Czernin J, Schwimmer J, et al. A tabulated summary of the FDG PET literature. J Nucl Med. 2001;42(suppl):1S-93S.
2. Wahl RL. Targeting glucose transporters for tumor imaging: "sweet" idea, "sour" result. J Nucl Med. 1996;37:1038-1041.
3. Pauwels EK, Ribeiro MJ, Stoot JH, et al. FDG accumulation and tumor biology. Nucl Med Biol. 1998;25:317-322.
4. Brown RS, Leung JY, Fisher S, et al., Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between glut-1 expression and FDG uptake. J Nucl Med. 1996;37:1042-1047.
5. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med. 1993;34:414-419.
6. 18F-FDG uptake in human endothelial cells in vitro. J Nucl Med. 2004;45:455-460.
7. Kim BT, Kim Y, Lee KS, et al. Localized form of broncheoalveolar carcinoma: FDG PET findings. AJR. 1998;170:935-939.
8. Fenchel S, Grab D, Nuessle K, et al. Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. Radiology. 2002;223:780-788.
9. 18F]FDG uptake in non-small cell lung cancer. Eur J Nucl Med. 2000;27:1778-1785.
10. Zhung H, Alavi A. 18-Fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med. 2002;32:47-59.
11. Kubota K, Matsuzawa T, Fujiwara T, et al. Differential diagnosis of lung tumor with positron emission tomography: a prospective study. J Nucl Med. 1990;31:1927-1932.
12. Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL. Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma. I. Are inflammatory cells important? J Nucl Med. 1995;36:1854-1861.
13. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972-1980.
14. Whiteford MH, Whiteford HM, Yee LF, et al. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum. 2000;43:759-767.
15. Higashi K, Ueda Y, Seki H, et al. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med. 1998;39:1016-1020.
16. Could MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA. 2001;285:914-924.
17. Goerres GW, von Schulthess GK, Hany TF. Positron emission tomography and PET CT of the head and neck: FDG uptake in normal anatomy, in benign lesions, and in changes resulting from treatment. AJR. 2002;179: 1337-1343.
18. Kamel EM, Goerres GW, Burger C, von Schulthess GK, Steinert HC. Recurrent laryngeal nerve palsy in patients with lung cancer: detection with PET-CT image fusion: report of six cases. Radiology. 2002;224:153-156.
19. 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab. 2003;88:4100-4104.
20. Bruel AVA, Maes A, Potter T, et al. Clinical relevance of thyroid fluorodeoxyglucose-whole body positron emission tomography incidentaloma. J Clin Endocrinol Metab. 2002;87:1517-1520.
21. Neely JR, Morgan HE. Relationship between carbohydrate and lipid metabolism and the energy balance of heat muscle. Annu Rev Physiol. 1974; 36:413-459.
22. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. RadioGraphics. 1999;19: 61-77.
23. Yasuda S, Ide M, Takagi S, Shohtsu A. Intrauterine accumulation of F-18 FDG during menstruation. Clin Nucl Med. 1997;22:793-794.
24. Chander S, Meltzer CC, McCook BM. Physiologic uterine uptake of FDG during menstruation demonstrated with serial combined positron emission tomography and computed tomography. Clin Nucl Med. 2002;27:22-24.
25. Cook GJ, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med. 1996;26:308-314.
26. Gordon BA, Flanagan FL, Dehdashti F. Whole-body positron emission tomography: normal variations, pitfalls, and technical considerations. AJR. 1997;169:1675-1680.
27. 18F-FDG uptake in the ovaries and uterus of healthy female volunteers. Eur J Nucl Med Mol Imaging. December 2004 [Epub ahead of print].
28. 18F-FDG PET/CT. J Nucl Med. 2003;44:1267-1270.
29. 18F-FDG PET/CT. J Nucl Med. 2003;44:170-176.
30. 18F-FDG PET. Radiographics. 2004;24:1611-1616.
31. Sugawara Y, Fisher SJ, Zasadny KR, Kison PV, Baker LH, Wahl RL. Preclinical and clinical studies of bone marrow uptake of fluorine-18- fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol. 1998;16:173-180.
32. Blodgett TM, Ames JT, Torok FS, McCook BM, Meltzer CC. Diffuse bone marrow uptake on whole-body F-18 fluorodeoxyglucose positron emission tomography in a patient taking recombinant erythropoietin. Clin Nucl Med. 2004;29:161-163.
33. Yao WJ, Hoh CK, Hawkins RA, et al. Quantitative PET imaging of bone marrow glucose metabolic response to hematopoietic cytokines. J Nucl Med. 1995;36:794-799.
34. Abdel-Dayem HM, Rosen G, El-Zeftawy H, et al. Fluorine-18 fluorodeoxyglucose splenic uptake from extramedullary hematopoiesis after granulocyte colony-stimulating factor stimulation. Clin Nucl Med. 1999;24:319-322.
35. Wong CL, Fulham MJ. Increased splenic FDG uptake on PET in beta-thalassemia. Clin Nucl Med. 2004;29:266-267.
36. Sumpe KD, Dazzi H, Schaffner A, von Schulthess GK. Infection imaging using whole-body FDG-PET. Eur J Nucl Med. 2000;27:822-832.
37. Alavi A, Gupta N, Alberini JL, et al. Positron emission tomography imaging in nonmalignant thoracic disorders. Semin Nucl Med. 2002;32: 293-321.
38. Bakheet SM, Powe J, Ezzat A, et al. F-18-FDG uptake in tuberculosis. Clin Nucl Med. 1998;23:739-742.
39. Bicik I, Bauerfeind P, Breitbach T, et al. Inflammatory bowel disease activity measured by positron-emission tomography. Lancet. 1997;350:262.
40. Lewis PJ, Salama A. Uptake of fluorine-18-deoxyglucose uptake in sarcoidosis. J Nucl Med. 1994;35:1647-1649.
41. Yasuda S, Shothsu A, Ide M, et al. High fluorine-18-deoxyglucose uptake in sarcoidosis. Clin Nucl Med. 1996;21:983-984.
42. Chen YK, Chen YL. Elevated F-18 FDG uptake in the thymus in Graves' disease. Clin Nucl Med. 2003;28:142-143.
43. Boerner AR, Voth E, Theissen P, Wienhard K, Wagner R, Schicha H. Glucose metabolism of the thyroid in Graves' disease measured by F-18-fluoro- deoxyglucose positron emission tomography. Thyroid. 1998;8:765-772.
44. Yun M, Yeh D, Araujo LI, Jang S, Newberg A, Alavi A. F-18 FDG uptake in the large arteries: a new observation. Clin Nucl Med. 2001;26:314-319.
45. 18F-FDG uptake in the large arteries: a correlation study with the atherogenic risk factors. Semin Nucl Med. 2002;32:70-76.
46. 18F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002;105:2708-2711.
47. Aoki J, Watanabe H, Shinozaki T, et al. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology. 2001;219:774-777.
48. 18F-FDG accumulations in the gastrointestinal tract in PET/CT: correlation with endoscopic and histopathologic results. J Nucl Med. 2004;45:1804-1810.